BioCentury
ARTICLE | Targets & Mechanisms

Epiphenomena at ASH

Epigenetics and cell therapies are preclinical hotspots at ASH 2017

December 8, 2017 2:10 AM UTC

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field that stumbled to capitalize on its early promise.

BioCentury’s survey of the 4,429 abstracts at this year’s meeting of the American Society of Hematology, which takes place Dec. 9-12 in Atlanta, Georgia, identified epigenetics and cell therapies as two of the meeting’s standout themes, each netting over 200 abstracts across a wide range of indications and development stages. ...